|
|
|
|
|
-
Wednesday, March 11, 2026
|
|
 |
|
ACN Newswire能提供全方位的服務。對於希望向媒體、業界和金融市場披露和傳播資訊的公司和組織,我們能為您安排即時的新聞發佈。ACN Newswire的新聞稿包括英文、簡體中文、繁體中文、韓文和日文等多種語言版本。
|
 |
|
|
|
|
| Saturday, 10 January 2026, 19:00 HKT/SGT | |
| | | | 來源 Promicell | |
|
|
佛羅里達州邁阿密, 2026年1月10日 - (亞太商訊) - PromiCell公司(下稱「本公司」)作為臨床階段細胞免疫療法企業,憑藉獨特優勢致力於為癌症患者開發潛在根治性細胞療法。本公司今日宣布,首席醫療官John Lee醫學博士將發表核心資產PRO CAR -201A(一種針對STEAP1的CAR-T細胞療法)的臨床中期成果。該療法目前正於加州舊金山舉行的「2026生物科技展示會」進行全球首例人體臨床I期試驗,用於治療轉移性去勢抵抗性前列腺癌(mCRPC)。發表時間為太平洋標準時間2025年1月12日(週一)上午11時15分,地點位於舊金山會議中心法蘭西斯會廳(宴會廳層)。(宴會廳層)舉行。
關於普瑞美細胞公司
PromiCell是一家臨床階段細胞免疫療法公司,其候選產品代表高度差異化且創新的CAR-T與TCR-T平台,將分別應用於實體腫瘤與血液腫瘤領域。我們的創新產品管線包含STEAP1 CAR-T細胞、HA-1 TCR-T細胞及CD33 CAR-T細胞,適用於治療mCRPC、尤文氏肉瘤、復發性白血病及急性骨髓性白血病患者。我們的新世代嵌合抗原受體CAR-T細胞療法,旨在突破腫瘤逃逸、疾病復發及免疫逃避等關鍵機制。本公司科學團隊身為CAR-T細胞療法先驅,秉持「智勝癌症、為患者創造更多治癒機會」的使命。更多資訊請參閱:www.promicell.com 。
聯絡方式: 305-433-1287 anthony@promicell.com
消息來源:Promicell
話題 Press release summary
部門 健康与医药, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025
Mar 11, 2026, 19:16 HKT/SGT
|
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 11, 2026, 19:15 HKT/SGT
|
|
|
MarketingPulse and eTailingPulse open next Thursday
Mar 11, 2026, 16:54 HKT/SGT
|
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Wednesday, March 11, 2026 11:07:00 AM
|
|
|
JOYY Reports 4Q and FY2025 Financial Results: Q4 Revenue Returns to YoY Growth, BIGO Ads Up 61.5% YoY
Mar 11, 2026, 09:40 HKT/SGT
|
|
|
Kincora Consolidates, Commences Geophysics and Forms Partnership at Cowal East
Mar 10, 2026, 17:59 HKT/SGT
|
|
|
Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs
Mar 10, 2026, 15:45 HKT/SGT
|
|
|
Impro Precision 2025 Profit Attributable to Shareholders Reaches Record High of HK$726.2 Million, Up 12.7% Year-on-Year, Forecast 2026 Sales Growth Rate to Accelerate to Mid-Double Digits
Mar 10, 2026, 14:19 HKT/SGT
|
|
|
Natural Beauty's 2025 Annual Results Show Steady & Robust Growth
Mar 10, 2026, 13:35 HKT/SGT
|
|
|
Xiamen C&D Inc.'s New Five-Year Strategic Plan Released, Aiming to Accelerate Globalization
Mar 10, 2026, 12:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
| Copyright © 2026 ACN Newswire - Asia Corporate News Network |
|
|
頂部 | 關於我們 | 服務 | 合作夥伴 | 聯繫 | 隱私權政策 | 使用條款 | RSS
|
|
|
美國: +1 214 890 4418 | 中國: +86 181 2376 3721 | 香港: +852 8192 4922 | 新加坡: +65 6549 7068 | 東京: +81 3 6859 8575
|
|
|
|
|
| |